GAMMA Investing LLC lifted its stake in National Research Corporation (NASDAQ:NRC - Free Report) by 45,978.8% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 15,206 shares of the company's stock after acquiring an additional 15,173 shares during the period. GAMMA Investing LLC owned 0.07% of National Research worth $195,000 at the end of the most recent reporting period.
A number of other institutional investors have also made changes to their positions in NRC. PNC Financial Services Group Inc. increased its position in National Research by 2,250.8% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,528 shares of the company's stock worth $27,000 after buying an additional 1,463 shares during the period. Tower Research Capital LLC TRC increased its position in National Research by 376.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,507 shares of the company's stock worth $44,000 after buying an additional 1,981 shares during the period. KLP Kapitalforvaltning AS bought a new position in National Research in the 4th quarter worth approximately $50,000. Signaturefd LLC increased its position in National Research by 613.3% in the 4th quarter. Signaturefd LLC now owns 4,173 shares of the company's stock worth $74,000 after buying an additional 3,588 shares during the period. Finally, Quadrant Capital Group LLC increased its position in National Research by 219.3% in the 4th quarter. Quadrant Capital Group LLC now owns 5,006 shares of the company's stock worth $88,000 after buying an additional 3,438 shares during the period. 47.26% of the stock is owned by institutional investors.
National Research Stock Performance
NASDAQ NRC traded down $0.65 during trading on Thursday, hitting $16.19. The company's stock had a trading volume of 86,151 shares, compared to its average volume of 94,274. The company has a quick ratio of 0.54, a current ratio of 0.54 and a debt-to-equity ratio of 1.98. The firm has a 50 day moving average price of $13.89 and a 200 day moving average price of $15.09. The firm has a market cap of $368.81 million, a P/E ratio of 15.72 and a beta of 0.38. National Research Corporation has a 52 week low of $9.76 and a 52 week high of $27.07.
National Research (NASDAQ:NRC - Get Free Report) last issued its quarterly earnings results on Monday, April 28th. The company reported $0.25 EPS for the quarter. The company had revenue of $33.55 million for the quarter. National Research had a return on equity of 71.33% and a net margin of 17.14%.
National Research Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, July 11th. Shareholders of record on Friday, June 27th will be given a $0.12 dividend. This represents a $0.48 annualized dividend and a yield of 2.96%. The ex-dividend date is Friday, June 27th. National Research's dividend payout ratio is currently 46.60%.
Insiders Place Their Bets
In other news, major shareholder Patrick E. Beans acquired 2,500 shares of the stock in a transaction dated Monday, May 12th. The shares were acquired at an average cost of $13.59 per share, for a total transaction of $33,975.00. Following the completion of the transaction, the insider now owns 35,003 shares in the company, valued at approximately $475,690.77. This trade represents a 7.69% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 8.10% of the company's stock.
About National Research
(
Free Report)
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty.
Read More

Before you consider National Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and National Research wasn't on the list.
While National Research currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.